This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Lin Fu
The Second Affiliated Hospital of Guangzhou Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Overexpression of microRNA-93 (miR-93) predicted worse outcome in non-small cell lung cancer (NSCLC) and gastric cancer patients, yet the prognostic role of miR-93 in AML is still unclear.
Methods: To further verify the prognostic significance of miR-93, the Cancer Genome Atlas database (TCGA) was screened and 161 AML patients with miR-93 expression information were included in our study.
Results: Compared with the patients who received chemotherapy alone with lower miR-93 expression, those with higher miR-93 expression had significantly longer event-free survival (EFS) and overall survival (OS) (all P < 0.05). Moreover, the expression levels of miR-93 was no association with either EFS or OS in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Multivariate analysis confirmed that high miR-93 expression was an independent favorable factor for EFS and OS in AML patients only receiving chemotherapy (all P < 0.05).
Conclusion: our study proved that high miR-93 expression could predict favorable prognosis in AML, but its prognostic effect could be overcome by allo-HSCT.
Keywords
Acute myeloid leukemia(AML), heterogeneity, miR-93, miR-99a, prognosis
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
The most recent version of this article is available here.
No community comments so far
Version 1
Posted 03 Jun, 2020
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Hematology
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Lin Fu
The Second Affiliated Hospital of Guangzhou Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
The most recent version of this article is available here.
No community comments so far
Version 1
Posted 03 Jun, 2020
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Hematology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The most recent version of this article is available here.
Background: Overexpression of microRNA-93 (miR-93) predicted worse outcome in non-small cell lung cancer (NSCLC) and gastric cancer patients, yet the prognostic role of miR-93 in AML is still unclear.
Methods: To further verify the prognostic significance of miR-93, the Cancer Genome Atlas database (TCGA) was screened and 161 AML patients with miR-93 expression information were included in our study.
Results: Compared with the patients who received chemotherapy alone with lower miR-93 expression, those with higher miR-93 expression had significantly longer event-free survival (EFS) and overall survival (OS) (all P < 0.05). Moreover, the expression levels of miR-93 was no association with either EFS or OS in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Multivariate analysis confirmed that high miR-93 expression was an independent favorable factor for EFS and OS in AML patients only receiving chemotherapy (all P < 0.05).
Conclusion: our study proved that high miR-93 expression could predict favorable prognosis in AML, but its prognostic effect could be overcome by allo-HSCT.
Figure 1
Figure 2
Loading...